Sonam Kapadia1, Sai Priyanka Gudiwada2, Amy H Kaji3, Rowan T Chlebowski4, Rose Venegas2, Junko Ozao-Choy1, Christine Dauphine1. 1. Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA. 2. Department of Pathology, Harbor-UCLA Medical Center, Torrance, CA, USA. 3. Department of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA. 4. Department of Medicine, Division of Medical Oncology, Harbor-UCLA Medical Center, Torrance, CA, USA.
Abstract
OBJECTIVE: To determine if clinicopathologic (CP) factors could identify patients at "very low" and/or "very high" pretest probability of a high Oncotype DX (ODX) score. METHODS: A retrospective analysis of all patients that had ODX testing 2008-2018 at a single institution. RESULTS: Of 215 patients, all 16 (7.4%) with "all high" risk CP factors had high ODX scores, and all 45 (20.9%) over age 50 with "all low" risk CP factors had ODX recommendations for no chemotherapy. CONCLUSIONS: Oncotype DX results did not change chemotherapy recommendations in those with "very low" or "very high" pretest probability of high ODX scores.
OBJECTIVE: To determine if clinicopathologic (CP) factors could identify patients at "very low" and/or "very high" pretest probability of a high Oncotype DX (ODX) score. METHODS: A retrospective analysis of all patients that had ODX testing 2008-2018 at a single institution. RESULTS: Of 215 patients, all 16 (7.4%) with "all high" risk CP factors had high ODX scores, and all 45 (20.9%) over age 50 with "all low" risk CP factors had ODX recommendations for no chemotherapy. CONCLUSIONS: Oncotype DX results did not change chemotherapy recommendations in those with "very low" or "very high" pretest probability of high ODX scores.